Clinical Trial Update: CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CAR2219 CAR-T cells for relapsed or refractory B-cell leukemia and B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• CAR2219

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Relapsed or Refractory B Cell Leukemia and Lymphoma | Phase 1, Phase 2 | Status: RECRUITING